The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Rheumatoid Arthritis: An Overview of New and Emerging Therapies
Abstract
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disorder characterized by symmetric inflammation of synovial joints leading to progressive erosion of cartilage and bone. The aim of treatment is to mitigate joint destruction, preserve function, and prevent disability. The American College of Rheumatology guidelines for the treatment of RA recommend that newly diagnosed patients with RA begin treatment with disease‐modifying antirheumatic drugs (DMARDs) within 3 months of diagnosis. Methotrexate remains the most commonly prescribed DMARD and is the standard by which recent new and emerging therapies are measured. Increasing knowledge regarding the immunologic basis of RA and advances in biotechnology have resulted in new, targeted biological therapies against proinflammatory cytokines that have dramatically changed the treatment paradigm and outcomes of patients with RA. This article reviews the pharmacological rationale underlying RA therapy, with a focus on currently available biological therapies and new therapies in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Madhok, R., Crilly, A., Watson, J., & Capell, H. A. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.3.232 · Cited by 340
Cited by
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27584 · Cited by 9,619
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138461 · Cited by 4,941
Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells
Jang, S., Kwon, E.-J., & Lee, J. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020905 · Cited by 612
Auranofin: Repurposing an Old Drug for a Golden New Age
Roder, C., & Thomson, M. J. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0083-y · Cited by 497
Therapeutic peptides: technological advances driving peptides into development
Sato, A. K., Viswanathan, M., Kent, R. B., & Wood, C. R. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.002 · Cited by 362
Metadata
- Authors
- Doan, T., & Massarotti, E.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-07
- Volume
- 45
- Issue
- 7
- Pages
- 751-762
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2101558198
- Cited by
- 171
- References
- 3
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rheumatoid Arthritis: An Overview of New and Emerging Therapies. https://app.cochat.ai/papers/10.1177/0091270005277938
- The paper
- Doan, T., & Massarotti, E. (2005). Rheumatoid Arthritis: An Overview of New and Emerging Therapies. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270005277938
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.